Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies placental dysfunction signatures
© 2024 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc..
Objectives: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infection in pregnancy is associated with higher incidence of placental dysfunction, referred to by a few studies as a 'preeclampsia-like syndrome'. However, the mechanisms underpinning SARS-CoV-2-induced placental malfunction are still unclear. Here, we investigated whether the transcriptional architecture of the placenta is altered in response to SARS-CoV-2 infection.
Methods: We utilised whole-transcriptome, digital spatial profiling, to examine gene expression patterns in placental tissues from participants who contracted SARS-CoV-2 in the third trimester of their pregnancy (n = 7) and those collected prior to the start of the coronavirus disease 2019 (COVID-19) pandemic (n = 9).
Results: Through comprehensive spatial transcriptomic analyses of the trophoblast and villous core stromal cell subpopulations in the placenta, we identified SARS-CoV-2 to promote signatures associated with hypoxia and placental dysfunction. Notably, genes associated with vasodilation (NOS3), oxidative stress (GDF15, CRH) and preeclampsia (FLT1, EGFR, KISS1, PAPPA2) were enriched with SARS-CoV-2. Pathways related to increased nutrient uptake, vascular tension, hypertension and inflammation were also enriched in SARS-CoV-2 samples compared to uninfected controls.
Conclusions: Our findings demonstrate the utility of spatially resolved transcriptomic analysis in defining the underlying pathogenic mechanisms of SARS-CoV-2 in pregnancy, particularly its role in placental dysfunction. Furthermore, this study highlights the significance of digital spatial profiling in mapping the intricate crosstalk between trophoblasts and villous core stromal cells, thus shedding light on pathways associated with placental dysfunction in pregnancies with SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical & translational immunology - 13(2024), 2 vom: 26., Seite e1488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stylianou, Nataly [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/cti2.1488 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368116859 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368116859 | ||
| 003 | DE-627 | ||
| 005 | 20240210233252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cti2.1488 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM368116859 | ||
| 035 | |a (NLM)38322491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stylianou, Nataly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies placental dysfunction signatures |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. | ||
| 520 | |a Objectives: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infection in pregnancy is associated with higher incidence of placental dysfunction, referred to by a few studies as a 'preeclampsia-like syndrome'. However, the mechanisms underpinning SARS-CoV-2-induced placental malfunction are still unclear. Here, we investigated whether the transcriptional architecture of the placenta is altered in response to SARS-CoV-2 infection | ||
| 520 | |a Methods: We utilised whole-transcriptome, digital spatial profiling, to examine gene expression patterns in placental tissues from participants who contracted SARS-CoV-2 in the third trimester of their pregnancy (n = 7) and those collected prior to the start of the coronavirus disease 2019 (COVID-19) pandemic (n = 9) | ||
| 520 | |a Results: Through comprehensive spatial transcriptomic analyses of the trophoblast and villous core stromal cell subpopulations in the placenta, we identified SARS-CoV-2 to promote signatures associated with hypoxia and placental dysfunction. Notably, genes associated with vasodilation (NOS3), oxidative stress (GDF15, CRH) and preeclampsia (FLT1, EGFR, KISS1, PAPPA2) were enriched with SARS-CoV-2. Pathways related to increased nutrient uptake, vascular tension, hypertension and inflammation were also enriched in SARS-CoV-2 samples compared to uninfected controls | ||
| 520 | |a Conclusions: Our findings demonstrate the utility of spatially resolved transcriptomic analysis in defining the underlying pathogenic mechanisms of SARS-CoV-2 in pregnancy, particularly its role in placental dysfunction. Furthermore, this study highlights the significance of digital spatial profiling in mapping the intricate crosstalk between trophoblasts and villous core stromal cells, thus shedding light on pathways associated with placental dysfunction in pregnancies with SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a digital spatial profiling | |
| 650 | 4 | |a gene expression profiling | |
| 650 | 4 | |a placental dysfunction | |
| 650 | 4 | |a trophoblasts | |
| 700 | 1 | |a Sebina, Ismail |e verfasserin |4 aut | |
| 700 | 1 | |a Matigian, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Monkman, James |e verfasserin |4 aut | |
| 700 | 1 | |a Doehler, Hadeel |e verfasserin |4 aut | |
| 700 | 1 | |a Röhl, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Allenby, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Liuliu |e verfasserin |4 aut | |
| 700 | 1 | |a Rockstroh, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghirad, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Sobanski, Thais |e verfasserin |4 aut | |
| 700 | 1 | |a O'Byrne, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, Ana Clara Simoes Florido |e verfasserin |4 aut | |
| 700 | 1 | |a Rebutini, Patricia Zadorosnei |e verfasserin |4 aut | |
| 700 | 1 | |a Machado-Souza, Cleber |e verfasserin |4 aut | |
| 700 | 1 | |a Stonoga, Emanuele Therezinha Schueda |e verfasserin |4 aut | |
| 700 | 1 | |a Warkiani, Majid E |e verfasserin |4 aut | |
| 700 | 1 | |a Salomon, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Kirsty |e verfasserin |4 aut | |
| 700 | 1 | |a McClements, Lana |e verfasserin |4 aut | |
| 700 | 1 | |a de Noronha, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ruby |e verfasserin |4 aut | |
| 700 | 1 | |a Belz, Gabrielle T |e verfasserin |4 aut | |
| 700 | 1 | |a Souza-Fonseca-Guimaraes, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Clifton, Vicki |e verfasserin |4 aut | |
| 700 | 1 | |a Kulasinghe, Arutha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational immunology |d 2012 |g 13(2024), 2 vom: 26., Seite e1488 |w (DE-627)NLM244580189 |x 2050-0068 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:2 |g day:26 |g pages:e1488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cti2.1488 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 2 |b 26 |h e1488 | ||